.24c Australian is equal to .18c American. Multiply by 20 for BNTC conversion, and we should be at $3.60 American. I believe it will retrace up, but given the volume, it may not be quite that much. I personally did not expect a lot with this announcement since applying for Orphan Designation is not the same as getting it. It really is a shame though. It could be assumed that seemingly placing HBV on the back-burner and focusing on AMD and OPMD could be viewed, albeit short-sightedly, as uncertainty to where the conpany’s own pipeline is going. But then HBV re-emerges in the quarterly call.
We just need to keep making progress, and not be discouraged. We are already more than double the sp than where we were a few months back.
